Skip to main content
Top
Published in: Acta Neurochirurgica 2/2015

01-02-2015 | Clinical Article - Brain Tumors

Combined use of 18 F-FDG PET and corticosteroid for diagnosis of deep-seated primary central nervous system lymphoma without histopathological confirmation

Authors: Shigeru Yamaguchi, Kenji Hirata, Sadahiro Kaneko, Hiroyuki Kobayashi, Tohru Shiga, Kentaro Kobayashi, Rikiya Onimaru, Hiroki Shirato, Nagara Tamaki, Shunsuke Terasaka, Kiyohiro Houkin

Published in: Acta Neurochirurgica | Issue 2/2015

Login to get access

Abstract

Background

Although histological diagnosis is indispensable in treating primary central nervous system lymphoma (PCNSL), we sometimes face an intractable situation in which tissue can be obtained only from a deep-seated brain lesion. In place of a histological diagnosis, the diagnostic adequacy of the combined use of 18 F-FDG PET and corticosteroid administration for PCNSL located in a deep-seated brain structure is reported.

Methods

Patients with a deep-seated tumor were treated as having PCNSL without histological confirmation, based on the following criteria: (1) there was no evidence of systemic malignancy; (2) the tumor showed an extremely high FDG uptake relative to normal gray matter on pretreatment 18 F-FDG PET; (3) the tumor decreased in size 1 week after diagnostic therapy by corticosteroid administration on contrast-enhanced T1-weighted magnetic resonance imaging (MRI). FDG uptake of the lesion was evaluated by the maximum of standardized uptake values (SUVmax) and tumor-to-normal ratio of the SUV (T/N ratio). The extent of the tumor reduction was calculated by volumetric analysis for the treatment response to corticosteroid administration.

Results

Ten patients (4 males and 6 females) matched these criteria. On pretreatment 18 F-FDG PET, mean SUVmax in the tumor was 24.8 (8.75–60.75), and mean T/N ratio was 3.24 (2.17–5.12). The extent of tumor volume reduction was shown to be 21 to 68 % 1 week after diagnostic therapy by corticosteroids. Mean total dose and duration of corticosteroids were 719 mg as prednisolone and 6.5 days, respectively. Nine patients achieved complete response and one patient achieved partial response on MRI after standard treatment for PCNSL with high-dose methotrexate and/or whole-brain irradiation.

Conclusion

Although the value of biopsy is universal, combining 18 F-FDG PET and corticosteroid administration is an important alternative method that may lead to the diagnosis of deep-seated PCNSLs in cases with intractable histopathological confirmations.
Literature
1.
go back to reference Andersen C, Haselgrove JC, Doenstrup S, Astrup J, Gyldensted C (1993) Resorption of peritumoural oedema in cerebral gliomas during dexamethasone treatment evaluated by NMR relaxation time imaging. Acta Neurochir (Wien) 122:218–224CrossRef Andersen C, Haselgrove JC, Doenstrup S, Astrup J, Gyldensted C (1993) Resorption of peritumoural oedema in cerebral gliomas during dexamethasone treatment evaluated by NMR relaxation time imaging. Acta Neurochir (Wien) 122:218–224CrossRef
2.
go back to reference Baraniskin A, Deckert M, Schulte-Altedorneburg G, Schlegel U, Schroers R (2011) Current strategies in the diagnosis of diffuse large B-cell lymphoma of the central nervous system. Br J Haematol 156:421–432PubMedCrossRef Baraniskin A, Deckert M, Schulte-Altedorneburg G, Schlegel U, Schroers R (2011) Current strategies in the diagnosis of diffuse large B-cell lymphoma of the central nervous system. Br J Haematol 156:421–432PubMedCrossRef
3.
go back to reference Bolat S, Berding G, Dengler R, Stangel M, Trebst C (2009) Fluorodeoxyglucose positron emission tomography (FDG-PET) is useful in the diagnosis of neurosarcoidosis. J Neurol Sci 287:257–259PubMedCrossRef Bolat S, Berding G, Dengler R, Stangel M, Trebst C (2009) Fluorodeoxyglucose positron emission tomography (FDG-PET) is useful in the diagnosis of neurosarcoidosis. J Neurol Sci 287:257–259PubMedCrossRef
4.
go back to reference Bromberg JE, Siemers MD, Taphoorn MJ (2002) Is a “vanishing tumor” always a lymphoma. Neurology 59:762–764PubMedCrossRef Bromberg JE, Siemers MD, Taphoorn MJ (2002) Is a “vanishing tumor” always a lymphoma. Neurology 59:762–764PubMedCrossRef
5.
go back to reference Hall WA (1998) The safety and efficacy of stereotactic biopsy for intracranial lesions. Cancer 82:1749–1755PubMedCrossRef Hall WA (1998) The safety and efficacy of stereotactic biopsy for intracranial lesions. Cancer 82:1749–1755PubMedCrossRef
6.
go back to reference Karantanis D, O’Eill BP, Subramaniam RM, Witte RJ, Mullan BP, Nathan MA, Lowe VJ, Peller PJ, Wiseman GA (2007) 18F-FDG PET/CT in primary central nervous system lymphoma in HIV-negative patients. Nucl Med Commun 28:834–841PubMedCrossRef Karantanis D, O’Eill BP, Subramaniam RM, Witte RJ, Mullan BP, Nathan MA, Lowe VJ, Peller PJ, Wiseman GA (2007) 18F-FDG PET/CT in primary central nervous system lymphoma in HIV-negative patients. Nucl Med Commun 28:834–841PubMedCrossRef
7.
go back to reference Kongkham PN, Knifed E, Tamber MS, Bernstein M (2008) Complications in 622 cases of frame-based stereotactic biopsy, a decreasing procedure. Can J Neurol Sci 35:79–84PubMedCrossRef Kongkham PN, Knifed E, Tamber MS, Bernstein M (2008) Complications in 622 cases of frame-based stereotactic biopsy, a decreasing procedure. Can J Neurol Sci 35:79–84PubMedCrossRef
8.
go back to reference Kuker W, Nagele T, Korfel A, Heckl S, Thiel E, Bamberg M, Weller M, Herrlinger U (2005) Primary central nervous system lymphomas (PCNSL): MRI features at presentation in 100 patients. J Neurooncol 72:169–177PubMedCrossRef Kuker W, Nagele T, Korfel A, Heckl S, Thiel E, Bamberg M, Weller M, Herrlinger U (2005) Primary central nervous system lymphomas (PCNSL): MRI features at presentation in 100 patients. J Neurooncol 72:169–177PubMedCrossRef
9.
go back to reference Makino K, Hirai T, Nakamura H, Murakami R, Kitajima M, Shigematsu Y, Nakashima R, Shiraishi S, Uetani H, Iwashita K, Akter M, Yamashita Y, Kuratsu J (2011) Does adding FDG-PET to MRI improve the differentiation between primary cerebral lymphoma and glioblastoma? Observer performance study. Ann Nucl Med 25:432–438PubMedCrossRef Makino K, Hirai T, Nakamura H, Murakami R, Kitajima M, Shigematsu Y, Nakashima R, Shiraishi S, Uetani H, Iwashita K, Akter M, Yamashita Y, Kuratsu J (2011) Does adding FDG-PET to MRI improve the differentiation between primary cerebral lymphoma and glioblastoma? Observer performance study. Ann Nucl Med 25:432–438PubMedCrossRef
10.
11.
go back to reference Mohile NA, Deangelis LM, Abrey LE (2008) Utility of brain FDG-PET in primary CNS lymphoma. Clin Adv Hematol Oncol 6(818–820):840 Mohile NA, Deangelis LM, Abrey LE (2008) Utility of brain FDG-PET in primary CNS lymphoma. Clin Adv Hematol Oncol 6(818–820):840
12.
go back to reference Ng D, Jacobs M, Mantil J (2006) Combined C-11 methionine and F-18 FDG PET imaging in a case of neurosarcoidosis. Clin Nucl Med 31:373–375PubMedCrossRef Ng D, Jacobs M, Mantil J (2006) Combined C-11 methionine and F-18 FDG PET imaging in a case of neurosarcoidosis. Clin Nucl Med 31:373–375PubMedCrossRef
13.
go back to reference Omuro AM, Leite CC, Mokhtari K, Delattre JY (2006) Pitfalls in the diagnosis of brain tumours. Lancet Neurol 5:937–948PubMedCrossRef Omuro AM, Leite CC, Mokhtari K, Delattre JY (2006) Pitfalls in the diagnosis of brain tumours. Lancet Neurol 5:937–948PubMedCrossRef
14.
go back to reference Reni M, Ferreri AJ, Garancini MP, Villa E (1997) Therapeutic management of primary central nervous system lymphoma in immunocompetent patients: results of a critical review of the literature. Ann Oncol 8:227–234PubMedCrossRef Reni M, Ferreri AJ, Garancini MP, Villa E (1997) Therapeutic management of primary central nervous system lymphoma in immunocompetent patients: results of a critical review of the literature. Ann Oncol 8:227–234PubMedCrossRef
15.
go back to reference Roelcke U, Leenders KL (1999) Positron emission tomography in patients with primary CNS lymphomas. J Neurooncol 43:231–236PubMedCrossRef Roelcke U, Leenders KL (1999) Positron emission tomography in patients with primary CNS lymphomas. J Neurooncol 43:231–236PubMedCrossRef
16.
go back to reference Rosenfeld SS, Hoffman JM, Coleman RE, Glantz MJ, Hanson MW, Schold SC (1992) Studies of primary central nervous system lymphoma with fluorine-18-fluorodeoxyglucose positron emission tomography. J Nucl Med 33:532–536PubMed Rosenfeld SS, Hoffman JM, Coleman RE, Glantz MJ, Hanson MW, Schold SC (1992) Studies of primary central nervous system lymphoma with fluorine-18-fluorodeoxyglucose positron emission tomography. J Nucl Med 33:532–536PubMed
17.
go back to reference Spaepen K, Stroobants S, Verhoef G, Mortelmans L (2003) Positron emission tomography with [(18)F]FDG for therapy response monitoring in lymphoma patients. Eur J Nucl Med Mol Imaging 30(Suppl 1):S97–105PubMedCrossRef Spaepen K, Stroobants S, Verhoef G, Mortelmans L (2003) Positron emission tomography with [(18)F]FDG for therapy response monitoring in lymphoma patients. Eur J Nucl Med Mol Imaging 30(Suppl 1):S97–105PubMedCrossRef
18.
go back to reference Yamaguchi S, Hirata K, Kobayashi H, Shiga T, Manabe O, Kobayashi K, Motegi H, Terasaka S, Houkin K (2014) The diagnostic role of (18)F-FDG PET for primary central nervous system lymphoma. Ann Nucl Med 28:603–609PubMedCrossRef Yamaguchi S, Hirata K, Kobayashi H, Shiga T, Manabe O, Kobayashi K, Motegi H, Terasaka S, Houkin K (2014) The diagnostic role of (18)F-FDG PET for primary central nervous system lymphoma. Ann Nucl Med 28:603–609PubMedCrossRef
19.
go back to reference Zacharia TT, Law M, Naidich TP, Leeds NE (2008) Central nervous system lymphoma characterization by diffusion-weighted imaging and MR spectroscopy. J Neuroimaging 18:411–417PubMedCrossRef Zacharia TT, Law M, Naidich TP, Leeds NE (2008) Central nervous system lymphoma characterization by diffusion-weighted imaging and MR spectroscopy. J Neuroimaging 18:411–417PubMedCrossRef
20.
go back to reference Zaki HS, Jenkinson MD, Du Plessis DG, Smith T, Rainov NG (2004) Vanishing contrast enhancement in malignant glioma after corticosteroid treatment. Acta Neurochir (Wien) 146:841–845CrossRef Zaki HS, Jenkinson MD, Du Plessis DG, Smith T, Rainov NG (2004) Vanishing contrast enhancement in malignant glioma after corticosteroid treatment. Acta Neurochir (Wien) 146:841–845CrossRef
Metadata
Title
Combined use of 18 F-FDG PET and corticosteroid for diagnosis of deep-seated primary central nervous system lymphoma without histopathological confirmation
Authors
Shigeru Yamaguchi
Kenji Hirata
Sadahiro Kaneko
Hiroyuki Kobayashi
Tohru Shiga
Kentaro Kobayashi
Rikiya Onimaru
Hiroki Shirato
Nagara Tamaki
Shunsuke Terasaka
Kiyohiro Houkin
Publication date
01-02-2015
Publisher
Springer Vienna
Published in
Acta Neurochirurgica / Issue 2/2015
Print ISSN: 0001-6268
Electronic ISSN: 0942-0940
DOI
https://doi.org/10.1007/s00701-014-2290-7

Other articles of this Issue 2/2015

Acta Neurochirurgica 2/2015 Go to the issue